

# Leverett

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	11	11.2	97.8	(48.8-175.1)	Female	1	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	3.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	4	11.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	1.9	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Male</u></b>				
Male	0	0.5	nc	(nc-nc)	Obs	30	44.3	67.8	(45.7-96.7)
Female	0	0.1	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Leukemia</u></b>					Obs				
Male	0	1.3	nc	(nc-nc)	34	36.5	93.2	(64.6-130.3)	
Female	2	0.7	nc	(nc-nc)	<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>Male</u></b>				
Male	5	6.4	78.2	(25.2-182.6)	Obs	0	1.2	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Female</u></b>					Obs				
Obs	4	5.4	nc	(nc-nc)	0	0.3	nc	(nc-nc)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lexington

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	42.5	61.2	(40.0-89.7)	Male	26	26.3	98.9	(64.6-144.9)
Female	3	15.4	nc	(nc-nc)	Female	24	20.6	116.8	(74.8-173.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	7.3	nc	(nc-nc)	Male	12	8.5	141.3	(72.9-246.9)
Female	6	6.6	91.0	(33.2-198.2)	Female	8	7.1	112.6	(48.5-221.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	1.5	nc	(nc-nc)	Male	19	23.2	81.8	(49.2-127.7)
Female	183	168.0	108.9	(93.7-125.9)	Female	21	20.8	101.1	(62.6-154.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	5.3	nc	(nc-nc)	Male	18	18.9	95.1	(56.4-150.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	37	43.5	85.1	(59.9-117.2)	Female	15	14.4	104.4	(58.4-172.2)
Female	28	44.5	62.9	(41.8-90.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	16	15.4	103.9	(59.4-168.8)
Male	5	10.3	48.4	(15.6-112.8)	Female	18	16.3	110.5	(65.4-174.6)
Female	1	3.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	129	120.5	107.0	(89.3-127.2)
Male	2	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	1	9.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	6.2	nc	(nc-nc)
Male	15	23.2	64.7	(36.2-106.7)	<b><u>Testis</u></b>				
Female	5	13.4	37.3	(12.0-87.0)	Male	6	4.3	139.3	(50.9-303.1)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	11	9.8	112.0	(55.8-200.4)
Female	0	1.9	nc	(nc-nc)	Female	34	28.9	117.7	(81.5-164.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	17	16.4	104.0	(60.5-166.5)	Female	32	37.4	85.6	(58.5-120.9)
Female	10	12.3	81.5	(39.0-149.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	416	518.7	80.2	(72.7-88.3)
Male	4	14.1	nc	(nc-nc)	Female	483	564.1	85.6	(78.2-93.6)
Female	5	5.0	99.6	(32.1-232.3)					
<b><u>Lung and Bronchus</u></b>									
Male	29	72.6	39.9	(26.7-57.4)					
Female	40	79.5	50.3	(35.9-68.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leyden

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	1	0.1	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	0.4	nc	(nc-nc)	Male	9	12.5	72.2	(32.9-137.0)
Female	0	0.1	nc	(nc-nc)	Female	16	12.5	127.7	(73.0-207.4)
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.6	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lincoln

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	9.9	nc	(nc-nc)	Male	7	6.0	117.6	(47.1-242.4)
Female	8	3.0	262.3	(113.0-516.9)	Female	7	4.1	171.2	(68.6-352.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	1.6	372.3	(135.9-810.4)	Male	3	1.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	44	31.9	137.9	(100.2-185.2)	Female	2	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	6	4.0	150.9	(55.1-328.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	9.8	71.4	(28.6-147.1)	Female	4	2.9	nc	(nc-nc)
Female	8	8.9	89.7	(38.6-176.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	3.5	143.1	(46.1-334.0)
Male	1	2.3	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	42	24.3	173.1	(124.8-234.0)
Male	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.2	nc	(nc-nc)
Male	1	4.9	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	4	2.6	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	6	5.7	105.9	(38.7-230.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	3.8	186.2	(74.6-383.7)	Female	13	7.2	179.5	(95.5-307.0)
Female	5	2.6	195.9	(63.1-457.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	118	114.1	103.4	(85.6-123.8)
Male	2	3.1	nc	(nc-nc)	Female	129	109.9	117.3	(98.0-139.4)
Female	1	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	16.3	36.7	(13.4-80.0)					
Female	9	15.1	59.6	(27.2-113.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Littleton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	9.2	142.0	(75.5-242.9)	Male	6	6.4	93.6	(34.2-203.7)
Female	1	3.9	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.6	142.3	(61.3-280.3)
Female	49	45.1	108.6	(80.4-143.6)	Female	5	5.4	93.1	(30.0-217.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	8	5.1	156.3	(67.3-307.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	10.3	58.0	(21.2-126.2)	Female	6	3.9	155.2	(56.7-337.7)
Female	8	11.3	70.9	(30.5-139.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	3.6	221.8	(95.5-437.1)
Male	1	2.5	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	35	30.7	114.0	(79.4-158.5)
Male	3	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.6	nc	(nc-nc)
Male	2	6.0	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	4	3.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	8	8.2	97.8	(42.1-192.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	3.9	153.3	(56.0-333.8)	Female	12	10.3	116.8	(60.3-204.1)
Female	3	3.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	131	126.7	103.4	(86.4-122.7)
Male	1	3.8	nc	(nc-nc)	Female	132	149.0	88.6	(74.1-105.1)
Female	1	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	17	16.7	101.8	(59.3-163.0)					
Female	14	20.8	67.4	(36.8-113.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	22.0	63.7	(34.8-106.9)	Male	16	13.3	120.4	(68.7-195.5)
Female	6	7.9	75.7	(27.6-164.7)	Female	12	10.2	117.3	(60.6-205.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	5	3.3	151.1	(48.7-352.7)	Female	1	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	11	11.7	94.4	(47.1-168.9)
Female	88	82.1	107.2	(86.0-132.1)	Female	11	10.4	105.5	(52.6-188.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.6	nc	(nc-nc)	Male	7	9.5	73.8	(29.5-152.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	14	22.3	62.7	(34.2-105.2)	Female	6	7.1	84.0	(30.7-182.8)
Female	13	23.2	56.0	(29.8-95.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	7.9	nc	(nc-nc)
Male	2	5.2	nc	(nc-nc)	Female	5	8.5	58.7	(18.9-137.0)
Female	1	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	50	61.0	81.9	(60.8-108.0)
Male	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	3.2	nc	(nc-nc)
Male	11	11.5	95.3	(47.5-170.6)	<b><u>Testis</u></b>				
Female	4	6.6	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	6	4.7	128.1	(46.8-278.7)
Female	0	0.9	nc	(nc-nc)	Female	8	13.8	57.8	(24.9-114.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	8.2	121.5	(58.2-223.5)	Female	13	18.0	72.1	(38.4-123.4)
Female	2	6.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	214	262.6	81.5	(70.9-93.2)
Male	4	7.1	nc	(nc-nc)	Female	236	281.4	83.9	(73.5-95.3)
Female	7	2.5	278.8	(111.7-574.5)					
<b><u>Lung and Bronchus</u></b>									
Male	26	37.1	70.1	(45.8-102.7)					
Female	23	39.6	58.0	(36.8-87.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lowell

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	81	82.9	97.7	(77.6-121.5)	Male	25	57.6	43.4	(28.1-64.0)
Female	35	32.1	108.9	(75.8-151.4)	Female	28	48.8	57.4	(38.1-82.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	13	19.5	66.8	(35.5-114.2)	Male	19	18.0	105.3	(63.4-164.5)
Female	12	16.6	72.1	(37.2-126.0)	Female	19	15.1	126.1	(75.9-196.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	34	51.6	65.9	(45.6-92.1)
Female	329	378.4	86.9	(77.8-96.9)	Female	36	45.5	79.1	(55.4-109.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	20	13.4	149.5	(91.3-230.8)	Male	59	45.3	130.2	(99.1-167.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	92	93.9	98.0	(79.0-120.1)	Female	32	32.9	97.3	(66.5-137.3)
Female	107	94.3	113.5	(93.0-137.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	20	22.3	89.8	(54.8-138.7)	Male	30	32.0	93.7	(63.2-133.7)
Female	6	6.3	95.7	(35.0-208.4)	Female	33	33.4	98.9	(68.1-138.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Stomach</u></b>				
Male	14	9.0	156.1	(85.3-262.0)	Male	23	20.4	112.8	(71.5-169.2)
Female	5	7.7	65.0	(21.0-151.8)	Female	33	13.3	249.0	(171.4-349.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Testis</u></b>				
Male	67	54.1	123.9	(96.0-157.3)	Male	14	18.0	77.9	(42.5-130.7)
Female	30	30.1	99.7	(67.3-142.4)	<b><u>Thyroid</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	13.1	114.8	(64.2-189.3)	Female	69	84.4	81.8	(63.6-103.5)
Female	7	4.1	171.3	(68.6-353.0)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	36	37.6	95.8	(67.1-132.7)	Male	1110	1144.8	97.0	(91.3-102.8)
Female	32	28.2	113.5	(77.6-160.2)	Female	1234	1263.9	97.6	(92.3-103.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	60	32.4	185.4	(141.5-238.7)	<b><u>All Sites / Types</u></b>				
Female	15	11.0	136.4	(76.3-225.0)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	175	147.1	119.0	(102.0-138.0)	<b><u>All Sites / Types</u></b>				
Female	188	168.9	111.3	(96.0-128.4)	<b><u>All Sites / Types</u></b>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ludlow

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	26.7	105.0	(69.8-151.8)	Male	11	17.0	64.6	(32.2-115.6)
Female	5	10.3	48.4	(15.6-112.9)	Female	13	13.3	97.7	(52.0-167.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.9	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	7	4.7	148.5	(59.5-306.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	15	15.0	99.7	(55.8-164.5)
Female	99	107.7	92.0	(74.7-112.0)	Female	16	13.7	116.6	(66.6-189.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	3.3	182.8	(66.7-397.9)	Male	6	12.8	47.0	(17.2-102.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	27	27.7	97.5	(64.2-141.8)	Female	8	9.4	85.5	(36.8-168.5)
Female	30	29.0	103.5	(69.8-147.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	9.9	101.1	(48.4-186.0)
Male	3	6.8	nc	(nc-nc)	Female	10	10.8	92.6	(44.3-170.2)
Female	2	2.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	50	81.2	61.5	(45.7-81.1)
Male	3	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	8	6.3	127.9	(55.1-252.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	4.1	121.6	(39.2-283.9)
Male	22	15.3	143.7	(90.0-217.6)	<b><u>Testis</u></b>				
Female	5	8.8	57.0	(18.4-133.0)	Male	1	3.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	3.9	126.8	(40.9-296.0)	Male	4	6.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	8	18.1	44.3	(19.1-87.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	10.5	57.0	(20.8-124.0)	Female	27	24.6	109.8	(72.3-159.7)
Female	7	8.0	87.2	(34.9-179.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	282	339.4	83.1	(73.7-93.4)
Male	10	9.6	103.7	(49.6-190.7)	Female	318	367.8	86.5	(77.2-96.5)
Female	2	3.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	35	46.7	74.9	(52.2-104.2)					
Female	32	53.4	59.9	(41.0-84.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	12.7	86.5	(43.1-154.7)	Male	10	8.1	122.9	(58.8-226.0)
Female	7	4.5	154.9	(62.1-319.3)	Female	2	6.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.3	nc	(nc-nc)	Male	5	2.6	192.5	(62.0-449.1)
Female	3	2.1	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.2	83.1	(30.3-180.9)
Female	64	54.9	116.6	(89.8-148.9)	Female	6	6.5	92.8	(33.9-202.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	6	6.1	98.1	(35.8-213.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	10	13.7	72.8	(34.8-133.8)	Female	2	4.6	nc	(nc-nc)
Female	15	13.1	114.6	(64.1-189.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	4.7	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	35	37.5	93.3	(65.0-129.8)
Male	3	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.9	nc	(nc-nc)
Male	7	7.4	94.8	(38.0-195.4)	<b><u>Testis</u></b>				
Female	3	4.2	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	5	3.3	150.8	(48.6-351.9)
Female	0	0.6	nc	(nc-nc)	Female	12	10.0	120.3	(62.1-210.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	5.0	158.7	(68.3-312.7)	Female	16	12.7	126.1	(72.0-204.8)
Female	6	3.7	163.7	(59.8-356.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	165	160.6	102.8	(87.7-119.7)
Male	3	4.4	nc	(nc-nc)	Female	171	177.6	96.3	(82.4-111.8)
Female	2	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	23	21.6	106.5	(67.5-159.8)					
Female	18	23.8	75.6	(44.8-119.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynn

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	84	72.8	115.4	(92.0-142.8)	Male	41	49.5	82.8	(59.4-112.4)
Female	26	27.6	94.2	(61.5-138.0)	Female	37	42.2	87.7	(61.7-120.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	19	16.3	116.5	(70.1-182.0)	Male	31	15.6	199.2	(135.3-282.8)
Female	20	14.4	139.0	(84.9-214.7)	Female	18	13.1	137.7	(81.6-217.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	2.6	189.1	(60.9-441.3)	Male	49	44.2	110.8	(82.0-146.5)
Female	307	329.9	93.1	(82.9-104.1)	Female	49	39.4	124.4	(92.1-164.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	16	11.6	138.0	(78.9-224.2)	Male	44	37.8	116.5	(84.6-156.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	117	80.9	144.6	(119.6-173.3)	Female	25	28.5	87.6	(56.7-129.3)
Female	112	81.3	137.8	(113.5-165.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	35	27.7	126.5	(88.1-175.9)
Male	15	19.0	79.0	(44.2-130.4)	Female	25	28.7	87.0	(56.3-128.5)
Female	4	5.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	284	225.3	126.1	(111.8-141.6)
Male	6	7.2	83.0	(30.3-180.7)	<b><u>Stomach</u></b>				
Female	3	6.4	nc	(nc-nc)	Male	20	17.7	113.3	(69.2-175.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	16	11.4	140.1	(80.0-227.5)
Male	40	45.6	87.7	(62.6-119.4)	<b><u>Testis</u></b>				
Female	29	26.1	111.0	(74.3-159.4)	Male	11	14.7	74.6	(37.2-133.5)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	12	11.1	107.8	(55.7-188.4)	Male	20	22.6	88.4	(53.9-136.5)
Female	5	3.6	140.5	(45.3-327.8)	Female	61	68.4	89.2	(68.3-114.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	44	32.1	137.2	(99.7-184.2)	Female	80	73.7	108.5	(86.0-135.0)
Female	29	24.5	118.4	(79.3-170.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	1209	975.5	123.9	(117.0-131.1)
Male	53	27.0	196.5	(147.2-257.0)	Female	1190	1095.0	108.7	(102.6-115.0)
Female	21	9.5	221.0	(136.7-337.8)					
<b><u>Lung and Bronchus</u></b>									
Male	197	128.0	153.9	(133.2-177.0)					
Female	179	145.4	123.1	(105.7-142.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynnfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	18.3	70.9	(37.7-121.2)	Male	26	11.1	233.8	(152.7-342.6)
Female	6	5.4	110.4	(40.3-240.4)	Female	12	7.4	161.6	(83.4-282.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	5	2.4	210.9	(68.0-492.3)	Female	5	2.5	196.6	(63.4-458.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	13	9.8	132.6	(70.6-226.8)
Female	67	61.4	109.2	(84.6-138.7)	Female	14	7.4	189.5	(103.5-318.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.9	nc	(nc-nc)	Male	5	7.9	63.3	(20.4-147.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	18.6	64.5	(33.3-112.6)	Female	8	5.2	153.0	(65.9-301.5)
Female	21	15.5	135.4	(83.8-206.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	6.6	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	Female	5	5.7	87.9	(28.3-205.1)
Female	1	1.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	40	50.4	79.3	(56.7-108.0)
Male	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.2	nc	(nc-nc)
Male	8	9.6	83.1	(35.8-163.7)	<b><u>Testis</u></b>				
Female	5	4.9	102.4	(33.0-239.0)	Male	7	1.7	403.6	(161.7-831.6)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	7	4.0	175.5	(70.3-361.7)
Female	0	0.7	nc	(nc-nc)	Female	17	10.7	158.5	(92.3-253.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	6.9	174.5	(90.1-304.8)	Female	15	13.9	107.5	(60.1-177.4)
Female	3	4.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	190	219.1	86.7	(74.8-99.9)
Male	2	5.9	nc	(nc-nc)	Female	226	203.5	111.0	(97.0-126.5)
Female	0	1.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	14	31.0	45.2	(24.7-75.9)					
Female	25	28.7	87.1	(56.3-128.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Malden

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	48.4	61.9	(41.8-88.4)	Male	10	33.4	30.0	(14.4-55.1)
Female	19	19.2	99.0	(59.6-154.7)	Female	12	29.1	41.3	(21.3-72.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	10.8	46.1	(14.9-107.6)	Male	10	10.4	95.8	(45.9-176.2)
Female	8	9.7	82.8	(35.7-163.2)	Female	4	9.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	47	29.8	157.5	(115.7-209.5)
Female	200	222.5	89.9	(77.9-103.2)	Female	23	27.1	84.7	(53.7-127.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	15	8.0	188.5	(105.4-310.9)	Male	29	25.2	115.1	(77.1-165.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	65	53.1	122.4	(94.4-156.0)	Female	16	19.4	82.6	(47.2-134.1)
Female	67	56.2	119.1	(92.3-151.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	19	18.5	102.8	(61.9-160.5)
Male	21	12.8	164.4	(101.7-251.2)	Female	20	20.0	99.8	(60.9-154.1)
Female	8	3.7	214.1	(92.2-422.0)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	144	152.2	94.6	(79.8-111.4)
Male	3	5.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	4.7	107.5	(34.6-250.8)	Male	20	11.8	169.9	(103.8-262.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	12	7.9	151.7	(78.3-265.0)
Male	32	30.5	104.9	(71.7-148.1)	<b><u>Testis</u></b>				
Female	20	17.7	112.8	(68.9-174.2)	Male	6	10.8	55.8	(20.4-121.4)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	7.5	66.3	(21.4-154.8)	Male	13	15.6	83.2	(44.3-142.3)
Female	2	2.4	nc	(nc-nc)	Female	56	47.1	119.0	(89.9-154.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	18	21.3	84.6	(50.1-133.8)	Female	41	49.8	82.4	(59.1-111.8)
Female	16	16.6	96.3	(55.0-156.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	655	655.5	99.9	(92.4-107.9)
Male	29	18.4	157.7	(105.6-226.6)	Female	728	748.3	97.3	(90.3-104.6)
Female	16	6.5	244.8	(139.8-397.5)					
<b><u>Lung and Bronchus</u></b>									
Male	114	86.3	132.1	(109.0-158.7)					
Female	99	100.1	98.9	(80.4-120.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	9.3	nc	(nc-nc)	Male	8	5.4	146.9	(63.2-289.5)
Female	1	2.8	nc	(nc-nc)	Female	5	3.7	136.6	(44.0-318.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	6	4.8	125.4	(45.8-273.0)
Female	32	31.1	102.9	(70.4-145.3)	Female	2	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	9.0	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	9	7.7	117.3	(53.5-222.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	23	25.7	89.6	(56.8-134.5)
Female	2	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	4.7	nc	(nc-nc)	Female	4	7.2	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	7	15.9	44.2	(17.7-91.0)
Female	0	0.9	nc	(nc-nc)	Female	8	15.0	53.4	(23.0-105.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mansfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	17.3	132.7	(84.1-199.2)	Male	20	12.5	160.4	(97.9-247.8)
Female	1	5.9	nc	(nc-nc)	Female	20	10.7	187.1	(114.2-288.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	4.2	192.5	(82.9-379.3)	Male	5	3.9	128.4	(41.4-299.8)
Female	6	3.5	170.7	(62.3-371.6)	Female	1	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	14	11.2	125.5	(68.5-210.5)
Female	99	87.5	113.1	(91.9-137.7)	Female	3	9.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	3.3	nc	(nc-nc)	Male	7	10.1	69.4	(27.8-142.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	20.6	116.6	(74.7-173.5)	Female	10	7.2	138.0	(66.1-253.8)
Female	27	19.1	141.6	(93.3-206.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	6.9	72.8	(23.5-169.9)
Male	1	4.8	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	62	58.7	105.5	(80.9-135.3)
Male	0	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	2.6	nc	(nc-nc)
Male	11	12.1	91.1	(45.4-163.1)	<b><u>Testis</u></b>				
Female	4	6.4	nc	(nc-nc)	Male	8	3.7	216.9	(93.4-427.4)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	13	6.2	208.9	(111.1-357.2)
Female	1	0.9	nc	(nc-nc)	Female	15	19.5	77.1	(43.1-127.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	7.9	101.1	(43.5-199.2)	Female	12	18.7	64.1	(33.1-112.0)
Female	8	5.6	143.8	(61.9-283.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	276	246.5	112.0	(99.1-126.0)
Male	10	7.0	142.2	(68.1-261.6)	Female	279	269.9	103.4	(91.6-116.2)
Female	3	2.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	37	30.9	119.6	(84.2-164.8)					
Female	28	32.3	86.6	(57.6-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marblehead

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	30.1	83.1	(53.8-122.7)	Male	41	18.3	224.0	(160.7-303.9)
Female	7	10.4	67.4	(27.0-138.9)	Female	24	13.8	174.2	(111.5-259.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.0	nc	(nc-nc)	Male	7	6.0	116.6	(46.7-240.3)
Female	4	4.4	nc	(nc-nc)	Female	8	4.8	166.0	(71.5-327.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	14	16.1	87.0	(47.5-145.9)
Female	113	115.7	97.7	(80.5-117.5)	Female	15	14.0	107.2	(59.9-176.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.5	nc	(nc-nc)	Male	12	13.0	92.0	(47.5-160.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	23	29.8	77.2	(48.9-115.8)	Female	5	9.8	50.9	(16.4-118.8)
Female	22	29.1	75.6	(47.3-114.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	10.8	73.7	(31.8-145.3)
Male	9	7.3	122.7	(56.0-233.0)	Female	15	10.8	138.9	(77.7-229.1)
Female	2	2.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	84	85.6	98.1	(78.2-121.5)
Male	0	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	1.4	nc	(nc-nc)	Male	6	6.8	87.6	(32.0-190.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	4.1	nc	(nc-nc)
Male	12	16.0	74.9	(38.6-130.8)	<b><u>Testis</u></b>				
Female	7	9.2	75.9	(30.4-156.3)	Male	3	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	4.2	nc	(nc-nc)	Male	7	6.3	110.9	(44.4-228.5)
Female	1	1.3	nc	(nc-nc)	Female	17	19.4	87.6	(51.0-140.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	12	11.3	105.9	(54.7-185.1)	Female	22	26.4	83.3	(52.2-126.2)
Female	9	8.0	112.4	(51.3-213.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	323	363.4	88.9	(79.5-99.1)
Male	2	10.0	nc	(nc-nc)	Female	357	383.5	93.1	(83.7-103.3)
Female	1	3.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	28	52.4	53.4	(35.5-77.2)					
Female	39	55.4	70.4	(50.1-96.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marion

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	7.9	89.0	(35.7-183.4)	Male	11	4.7	235.4	(117.4-421.3)
Female	5	3.0	167.3	(53.9-390.3)	Female	2	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	10	4.2	239.8	(114.8-441.0)
Female	31	29.3	105.6	(71.8-150.0)	Female	3	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	7.6	144.3	(72.0-258.3)	Female	0	2.5	nc	(nc-nc)
Female	10	8.3	120.5	(57.7-221.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	2.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	14	22.9	61.2	(33.5-102.8)
Male	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.2	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	4.5	134.4	(49.1-292.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	2.9	206.7	(75.5-449.9)	Female	7	6.7	104.4	(41.8-215.1)
Female	4	2.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	99	94.4	104.9	(85.2-127.7)
Male	0	2.5	nc	(nc-nc)	Female	108	101.9	106.0	(86.9-128.0)
Female	1	0.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	10	13.6	73.4	(35.1-134.9)					
Female	16	15.1	106.1	(60.6-172.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	36	39.6	90.8	(63.6-125.8)	Male	26	26.5	98.3	(64.2-144.0)
Female	12	13.4	89.6	(46.3-156.6)	Female	13	19.8	65.6	(34.9-112.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	8.1	86.0	(34.5-177.2)	Male	9	8.4	107.7	(49.2-204.5)
Female	10	6.5	154.3	(73.9-283.7)	Female	7	6.3	110.9	(44.4-228.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	16	23.3	68.6	(39.2-111.3)
Female	152	158.0	96.2	(81.5-112.8)	Female	26	18.9	137.5	(89.8-201.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	5.5	163.3	(74.5-310.1)	Male	19	19.9	95.4	(57.4-149.0)
<b><u>Colon / Rectum</u></b>					Female	20	8.4	237.6	(145.1-367.0)
Male	43	43.0	100.0	(72.3-134.7)	<b><u>Ovary</u></b>				
Female	44	38.6	114.0	(82.8-153.0)	Female	16	13.5	118.3	(67.6-192.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	10.2	97.8	(46.8-179.9)	Male	14	14.9	94.0	(51.3-157.7)
Female	5	2.6	190.5	(61.4-444.5)	Female	15	13.8	108.3	(60.6-178.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	7	3.4	208.2	(83.4-428.9)	Male	102	120.6	84.6	(69.0-102.7)
Female	3	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	9.5	nc	(nc-nc)
Male	15	24.1	62.2	(34.8-102.7)	Female	7	5.4	129.9	(52.0-267.6)
Female	13	12.5	103.9	(55.3-177.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	6.8	nc	(nc-nc)
Male	6	6.0	100.3	(36.6-218.2)	<b><u>Thyroid</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	13	11.5	113.2	(60.2-193.6)
<b><u>Leukemia</u></b>					Female	38	31.4	120.9	(85.5-165.9)
Male	12	16.6	72.1	(37.2-125.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	11.2	125.0	(68.3-209.7)	Female	36	35.8	100.6	(70.4-139.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	14.5	96.3	(52.6-161.6)	Male	445	519.6	85.6	(77.9-94.0)
Female	7	4.6	152.7	(61.2-314.6)	Female	569	522.5	108.9	(100.1-118.2)
<b><u>Lung and Bronchus</u></b>									
Male	56	70.0	80.0	(60.4-103.9)					
Female	76	71.3	106.6	(84.0-133.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marshfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	29.0	82.8	(53.0-123.2)	Male	31	19.1	162.4	(110.3-230.5)
Female	10	9.7	103.1	(49.4-189.7)	Female	29	14.4	201.1	(134.6-288.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	5.6	196.6	(98.0-351.8)	Male	10	6.2	162.1	(77.6-298.1)
Female	4	4.7	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	10	16.8	59.5	(28.5-109.5)
Female	145	121.4	119.5	(100.8-140.6)	Female	13	13.9	93.4	(49.7-159.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.9	nc	(nc-nc)	Male	17	15.0	113.2	(65.9-181.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	23	31.3	73.4	(46.5-110.2)	Female	8	10.2	78.7	(33.9-155.1)
Female	27	27.6	97.9	(64.5-142.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	11.1	108.5	(56.0-189.6)
Male	7	7.7	91.0	(36.5-187.6)	Female	10	10.0	100.5	(48.1-184.8)
Female	0	2.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	102	95.1	107.2	(87.4-130.2)
Male	0	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.7	nc	(nc-nc)	Male	5	7.0	71.8	(23.1-167.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	3.9	nc	(nc-nc)
Male	20	17.9	111.6	(68.2-172.4)	<b><u>Testis</u></b>				
Female	6	9.4	63.9	(23.3-139.2)	Male	5	3.6	140.6	(45.3-328.2)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	4.5	nc	(nc-nc)	Male	8	7.8	102.4	(44.1-201.8)
Female	1	1.4	nc	(nc-nc)	Female	17	22.4	75.9	(44.2-121.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	11.8	127.5	(71.3-210.2)	Female	21	28.3	74.3	(46.0-113.6)
Female	5	7.9	63.4	(20.4-147.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	392	384.5	102.0	(92.1-112.6)
Male	13	11.0	118.5	(63.0-202.7)	Female	414	389.2	106.4	(96.4-117.1)
Female	0	3.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	49	51.9	94.4	(69.8-124.8)					
Female	71	53.3	133.3	(104.1-168.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mashpee

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	24.6	101.7	(65.8-150.2)	Male	17	14.4	118.4	(68.9-189.5)
Female	6	8.8	68.5	(25.0-149.1)	Female	16	10.5	152.9	(87.4-248.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.8	nc	(nc-nc)	Male	10	4.8	209.5	(100.3-385.3)
Female	1	3.4	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	18	12.6	143.0	(84.7-226.0)
Female	96	89.4	107.3	(86.9-131.1)	Female	10	11.4	88.0	(42.1-161.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.4	nc	(nc-nc)	Male	14	9.8	143.4	(78.3-240.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	23.1	69.2	(39.5-112.4)	Female	4	7.7	nc	(nc-nc)
Female	19	23.2	81.7	(49.2-127.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	8.6	115.9	(55.5-213.1)
Male	5	5.8	85.5	(27.6-199.6)	Female	8	9.0	89.2	(38.4-175.7)
Female	0	1.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	60	67.7	88.7	(67.7-114.1)
Male	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.3	nc	(nc-nc)
Male	7	12.2	57.2	(22.9-117.8)	<b><u>Testis</u></b>				
Female	7	7.4	94.3	(37.8-194.2)	Male	3	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	7	13.1	53.4	(21.4-109.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	8.9	90.3	(38.9-177.9)	Female	18	20.9	86.0	(50.9-135.9)
Female	11	6.4	171.6	(85.6-307.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	275	286.8	95.9	(84.9-107.9)
Male	5	7.7	65.3	(21.0-152.4)	Female	302	304.4	99.2	(88.3-111.1)
Female	1	2.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	40	43.0	93.1	(66.5-126.8)					
Female	57	47.6	119.9	(90.8-155.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	8.4	142.4	(73.5-248.8)	Male	4	5.3	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	37	33.5	110.5	(77.8-152.3)	Female	4	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	13	4.0	328.8	(174.9-562.4)
<b><u>Colon / Rectum</u></b>					Female	2	1.8	nc	(nc-nc)
Male	13	8.6	151.7	(80.7-259.5)	<b><u>Ovary</u></b>				
Female	3	8.0	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	35	26.6	131.5	(91.6-182.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.0	nc	(nc-nc)
Male	4	4.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	5.6	89.9	(29.0-209.7)
Male	1	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.2	nc	(nc-nc)	Female	9	7.8	115.3	(52.6-219.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	123	106.9	115.0	(95.6-137.2)
Female	3	1.0	nc	(nc-nc)	Female	99	109.8	90.2	(73.3-109.8)
<b><u>Lung and Bronchus</u></b>									
Male	15	15.0	99.7	(55.8-164.5)					
Female	14	16.1	86.9	(47.5-145.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	13.8	65.4	(29.9-124.2)	Male	10	8.8	113.9	(54.6-209.6)
Female	4	3.6	nc	(nc-nc)	Female	5	5.5	91.0	(29.3-212.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
Female	37	43.8	84.6	(59.5-116.6)	Female	3	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	6	6.4	94.1	(34.3-204.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	14.1	120.7	(70.3-193.3)	Female	3	3.8	nc	(nc-nc)
Female	15	10.5	142.6	(79.7-235.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	5.1	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	5	3.7	133.9	(43.2-312.5)
Female	1	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	22	40.3	54.6	(34.2-82.6)
Male	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.5	nc	(nc-nc)
Male	2	7.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	4	3.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	9	8.5	105.8	(48.3-200.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	5.5	nc	(nc-nc)	Female	5	10.4	48.0	(15.5-112.0)
Female	6	3.0	199.0	(72.7-433.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	109	172.8	63.1	(51.8-76.1)
Male	2	4.9	nc	(nc-nc)	Female	139	143.7	96.8	(81.3-114.3)
Female	2	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	12	24.2	49.6	(25.6-86.6)					
Female	20	19.2	104.2	(63.6-161.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	12.8	62.6	(26.9-123.3)	Male	14	8.7	161.1	(88.0-270.3)
Female	4	3.8	nc	(nc-nc)	Female	5	6.3	79.6	(25.7-185.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	2.6	232.7	(85.0-506.6)	Male	2	2.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	5	7.7	65.0	(20.9-151.7)
Female	39	53.6	72.8	(51.8-99.5)	Female	4	5.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.9	nc	(nc-nc)	Male	6	6.7	88.9	(32.5-193.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	14.3	111.8	(63.9-181.6)	Female	4	4.4	nc	(nc-nc)
Female	10	12.0	83.6	(40.0-153.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	5.0	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	53	40.0	132.5	(99.3-173.3)
Male	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.6	nc	(nc-nc)
Male	7	8.1	86.9	(34.8-179.1)	<b><u>Testis</u></b>				
Female	3	4.0	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	10.7	56.2	(20.5-122.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	5.3	nc	(nc-nc)	Female	10	11.7	85.6	(41.0-157.5)
Female	3	3.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	155	170.3	91.0	(77.3-106.5)
Male	0	4.9	nc	(nc-nc)	Female	123	165.6	74.3	(61.7-88.6)
Female	1	1.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	11	22.7	48.5	(24.2-86.9)					
Female	14	20.7	67.5	(36.9-113.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	56	57.1	98.0	(74.0-127.3)	Male	17	36.0	47.3	(27.5-75.7)
Female	22	21.9	100.4	(62.9-152.0)	Female	17	30.6	55.6	(32.4-89.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	10.9	109.8	(56.7-191.8)	Male	11	11.4	96.8	(48.3-173.3)
Female	10	10.1	98.8	(47.3-181.8)	Female	9	10.1	89.1	(40.6-169.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	30	32.0	93.7	(63.2-133.8)
Female	233	234.0	99.6	(87.2-113.2)	Female	29	29.9	96.9	(64.9-139.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	7.8	77.4	(28.3-168.4)	Male	24	25.3	94.9	(60.8-141.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	62	58.6	105.8	(81.1-135.7)	Female	19	20.7	91.7	(55.2-143.2)
Female	70	61.7	113.4	(88.4-143.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	14	13.8	101.6	(55.5-170.4)	Male	17	20.6	82.6	(48.1-132.3)
Female	8	4.2	189.5	(81.6-373.4)	Female	22	22.7	96.8	(60.7-146.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	4.8	104.6	(33.7-244.2)	Male	148	159.3	92.9	(78.6-109.2)
Female	5	4.7	107.3	(34.6-250.4)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	28	31.1	89.9	(59.8-130.0)	Male	13	13.1	98.9	(52.6-169.1)
Female	21	19.2	109.6	(67.8-167.5)	Female	9	8.7	103.0	(47.0-195.5)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	7	8.0	87.6	(35.1-180.5)	Male	10	9.4	106.8	(51.1-196.5)
Female	3	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	30	23.1	130.0	(87.7-185.6)	Male	13	14.3	91.0	(48.4-155.7)
Female	23	18.0	127.9	(81.1-192.0)	Female	44	45.6	96.4	(70.0-129.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	27	18.9	142.7	(94.0-207.6)	Female	55	53.5	102.8	(77.5-133.9)
Female	6	7.3	82.1	(30.0-178.8)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	105	98.4	106.8	(87.3-129.2)	Male	685	706.1	97.0	(89.9-104.6)
Female	142	113.9	124.7	(105.0-147.0)	Female	834	805.9	103.5	(96.6-110.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medway

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	11.2	98.2	(49.0-175.8)	Male	9	7.8	116.0	(52.9-220.2)
Female	3	4.6	nc	(nc-nc)	Female	5	7.1	70.6	(22.8-164.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	11	6.9	158.8	(79.1-284.1)
Female	63	56.9	110.7	(85.1-141.7)	Female	10	6.6	151.4	(72.5-278.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	1	6.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	13.1	122.1	(69.7-198.3)	Female	7	4.8	145.5	(58.3-299.8)
Female	10	14.4	69.7	(33.4-128.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	4.4	114.6	(36.9-267.5)
Male	4	3.1	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	55	37.2	148.0	(111.5-192.7)
Male	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	2.0	nc	(nc-nc)
Male	7	7.5	93.6	(37.5-192.9)	<b><u>Testis</u></b>				
Female	5	4.4	114.9	(37.0-268.2)	Male	2	1.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	6	3.5	169.8	(62.0-369.5)
Female	0	0.6	nc	(nc-nc)	Female	10	11.3	88.7	(42.5-163.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	4.8	nc	(nc-nc)	Female	15	12.3	121.7	(68.1-200.7)
Female	6	4.0	150.7	(55.0-327.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	179	154.7	115.7	(99.4-133.9)
Male	5	4.4	112.7	(36.3-263.0)	Female	189	184.5	102.4	(88.4-118.1)
Female	3	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	19.9	95.3	(57.3-148.8)					
Female	23	23.4	98.4	(62.4-147.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Melrose

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	29.5	44.1	(23.5-75.4)	Male	16	19.1	83.8	(47.9-136.2)
Female	8	11.2	71.2	(30.6-140.2)	Female	20	15.7	127.3	(77.7-196.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.8	nc	(nc-nc)	Male	7	6.1	115.1	(46.1-237.1)
Female	7	5.0	138.8	(55.6-286.0)	Female	2	5.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	21	16.9	124.1	(76.8-189.6)
Female	134	125.5	106.7	(89.4-126.4)	Female	22	15.5	142.1	(89.0-215.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.2	nc	(nc-nc)	Male	11	14.2	77.4	(38.6-138.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	43	31.2	137.9	(99.8-185.8)	Female	5	10.8	46.2	(14.9-107.8)
Female	40	32.0	125.2	(89.4-170.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	16	10.9	146.4	(83.7-237.8)
Male	9	7.5	120.0	(54.8-227.8)	Female	13	11.7	111.2	(59.1-190.1)
Female	1	2.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	79	90.2	87.6	(69.3-109.2)
Male	1	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	9	7.0	129.2	(59.0-245.3)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	4.5	nc	(nc-nc)
Male	14	17.4	80.4	(43.9-134.9)	<b><u>Testis</u></b>				
Female	6	10.1	59.3	(21.7-129.1)	Male	3	4.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	4.3	161.8	(64.8-333.5)	Male	8	8.1	99.0	(42.6-195.0)
Female	1	1.4	nc	(nc-nc)	Female	23	23.3	98.6	(62.5-147.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	12.1	165.7	(101.2-255.9)	Female	35	28.7	122.0	(85.0-169.7)
Female	9	9.1	98.6	(45.0-187.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	361	379.9	95.0	(85.5-105.4)
Male	7	10.4	67.3	(26.9-138.6)	Female	438	421.6	103.9	(94.4-114.1)
Female	5	3.8	132.6	(42.7-309.4)					
<b><u>Lung and Bronchus</u></b>									
Male	41	51.4	79.8	(57.3-108.3)					
Female	60	59.3	101.2	(77.3-130.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mendon

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	6.5	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	5	3.9	128.1	(41.3-299.1)
Female	18	25.6	70.4	(41.7-111.3)	Female	4	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	7.4	81.6	(29.8-177.5)	Female	2	2.1	nc	(nc-nc)
Female	6	5.0	120.1	(43.9-261.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	18	24.0	74.9	(44.4-118.4)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	4.4	114.8	(37.0-268.0)	Female	8	5.9	135.2	(58.2-266.4)
Female	1	1.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.1	nc	(nc-nc)	Female	8	5.9	135.2	(58.2-266.4)
Female	0	0.3	nc	(nc-nc)	Male	64	91.1	70.2	(54.1-89.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	2.7	nc	(nc-nc)	Female	80	76.7	104.3	(82.7-129.9)
Female	1	1.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.7	nc	(nc-nc)	Male	64	91.1	70.2	(54.1-89.7)
Female	1	0.6	nc	(nc-nc)	Female	80	76.7	104.3	(82.7-129.9)
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	11.7	68.4	(29.4-134.7)	Male	64	91.1	70.2	(54.1-89.7)
Female	10	9.3	107.4	(51.4-197.6)	Female	80	76.7	104.3	(82.7-129.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Merrimac

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.3	122.5	(55.9-232.5)	Male	3	4.8	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	26	31.8	81.6	(53.3-119.6)	Female	3	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	7.8	102.2	(44.0-201.4)	Female	4	2.7	nc	(nc-nc)
Female	6	7.3	82.6	(30.2-179.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	18	24.0	75.0	(44.4-118.5)
Female	2	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	4.5	nc	(nc-nc)	Female	1	7.3	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	16	13.3	120.7	(69.0-196.1)
Female	3	0.9	nc	(nc-nc)	Female	24	13.6	176.9	(113.3-263.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Methuen

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	53	49.5	107.1	(80.2-140.0)	Male	24	32.3	74.3	(47.6-110.5)
Female	23	18.2	126.1	(79.9-189.2)	Female	20	26.0	76.9	(46.9-118.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	9.8	122.7	(63.3-214.4)	Male	7	10.3	68.0	(27.2-140.1)
Female	10	8.4	118.4	(56.7-217.7)	Female	8	8.5	93.9	(40.4-185.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	36	28.7	125.5	(87.9-173.8)
Female	186	208.7	89.1	(76.8-102.9)	Female	24	25.3	94.9	(60.8-141.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.9	86.9	(31.7-189.0)	Male	25	24.3	102.7	(66.5-151.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	48	52.6	91.2	(67.2-120.9)	Female	21	18.0	116.7	(72.2-178.4)
Female	44	52.1	84.4	(61.3-113.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	18.6	64.5	(33.3-112.7)
Male	9	12.7	70.9	(32.3-134.6)	Female	23	18.9	121.9	(77.2-182.8)
Female	3	3.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	158	152.5	103.6	(88.1-121.1)
Male	6	3.9	155.4	(56.7-338.2)	<b><u>Stomach</u></b>				
Female	0	3.4	nc	(nc-nc)	Male	12	11.7	102.1	(52.7-178.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	9	7.3	122.9	(56.1-233.4)
Male	36	29.3	122.9	(86.1-170.2)	<b><u>Testis</u></b>				
Female	20	16.6	120.1	(73.4-185.6)	Male	12	7.2	165.8	(85.6-289.7)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	10	7.4	134.5	(64.4-247.5)	Male	18	13.4	134.3	(79.5-212.2)
Female	6	2.3	258.0	(94.2-561.7)	Female	45	39.6	113.6	(82.9-152.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	26	20.4	127.2	(83.1-186.4)	Female	50	47.3	105.6	(78.4-139.3)
Female	15	14.8	101.0	(56.5-166.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	663	642.1	103.3	(95.5-111.4)
Male	15	18.0	83.2	(46.5-137.2)	Female	733	695.0	105.5	(98.0-113.4)
Female	6	6.1	98.1	(35.8-213.5)					
<b><u>Lung and Bronchus</u></b>									
Male	101	86.7	116.6	(94.9-141.6)					
Female	133	96.9	137.2	(114.9-162.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	37	25.4	145.9	(102.7-201.1)	Male	17	16.6	102.1	(59.5-163.5)
Female	10	9.3	107.7	(51.6-198.1)	Female	15	13.2	113.8	(63.7-187.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.1	136.3	(54.6-280.8)	Male	5	5.4	92.5	(29.8-215.8)
Female	6	4.2	141.5	(51.7-308.1)	Female	6	4.4	137.7	(50.3-299.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	17	14.8	115.1	(67.0-184.2)
Female	109	108.3	100.6	(82.6-121.4)	Female	11	12.9	85.5	(42.6-153.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.6	nc	(nc-nc)	Male	15	13.1	114.7	(64.2-189.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	26	27.3	95.1	(62.1-139.3)	Female	10	9.2	109.2	(52.3-200.8)
Female	24	26.4	91.0	(58.3-135.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	13	9.6	134.7	(71.7-230.4)
Male	10	6.7	148.3	(71.0-272.8)	Female	12	9.7	124.3	(64.2-217.1)
Female	3	1.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	86	84.7	101.5	(81.2-125.4)
Male	1	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	6	6.1	98.3	(35.9-214.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.7	nc	(nc-nc)
Male	23	15.8	145.8	(92.4-218.7)	<b><u>Testis</u></b>				
Female	6	8.5	70.2	(25.6-152.8)	Male	4	3.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	8	6.9	115.8	(49.9-228.2)
Female	5	1.2	412.4	(132.9-962.5)	Female	25	20.2	123.8	(80.1-182.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	10.5	105.1	(52.4-188.1)	Female	33	24.7	133.6	(92.0-187.6)
Female	10	7.4	134.9	(64.6-248.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	393	338.9	116.0	(104.8-128.0)
Male	12	9.6	125.4	(64.7-219.1)	Female	412	356.8	115.5	(104.6-127.2)
Female	6	3.1	193.9	(70.8-422.0)					
<b><u>Lung and Bronchus</u></b>									
Male	67	45.6	146.8	(113.8-186.4)					
Female	80	50.1	159.7	(126.6-198.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middlefield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	1.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Male</u></b>				
Male	0	0.2	nc	(nc-nc)	7	13.3	52.7	(21.1-108.6)	
Female	0	0.0	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Leukemia</u></b>					<b><u>8</u></b>				
Male	0	0.4	nc	(nc-nc)	9.7	82.9	(35.7-163.3)		
Female	0	0.2	nc	(nc-nc)					
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	0	0.4	nc	(nc-nc)					
Female	1	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	0	1.9	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	11.0	154.2	(89.8-246.9)	Male	8	7.4	107.5	(46.3-211.8)
Female	3	3.0	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.3	216.6	(69.8-505.6)	Male	2	2.3	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	12	6.6	181.0	(93.4-316.2)
Female	38	35.5	107.0	(75.7-146.9)	Female	8	4.2	192.3	(82.8-378.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	5	5.9	85.1	(27.4-198.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	12.3	89.6	(44.7-160.4)	Female	0	3.0	nc	(nc-nc)
Female	11	8.4	130.9	(65.3-234.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	35	36.4	96.3	(67.0-133.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	7.0	nc	(nc-nc)	Female	15	8.2	183.6	(102.7-302.9)
Female	4	2.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	3	1.7	nc	(nc-nc)	Male	5	4.7	107.3	(34.6-250.5)
Female	0	0.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	2	4.2	nc	(nc-nc)	Male	17	19.4	87.7	(51.1-140.5)
Female	1	1.0	nc	(nc-nc)	Female	21	16.8	125.1	(77.4-191.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	26.3	159.5	(114.9-215.6)	Male	15	17.8	84.2	(47.1-138.9)
Female	17	9.8	173.0	(100.7-277.0)	Female	13	14.6	89.0	(47.3-152.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.5	90.1	(29.0-210.3)	Male	2	5.7	nc	(nc-nc)
Female	5	4.8	104.8	(33.8-244.6)	Female	10	4.7	213.7	(102.3-393.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	22	15.8	138.9	(87.0-210.3)
Female	114	116.9	97.5	(80.4-117.1)	Female	18	13.9	129.2	(76.6-204.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.0	125.4	(40.4-292.7)	Male	18	13.6	131.9	(78.1-208.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	32	29.2	109.6	(75.0-154.7)	Female	9	10.0	90.0	(41.1-170.9)
Female	29	28.6	101.3	(67.8-145.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	10.0	99.8	(47.8-183.5)
Male	8	6.9	115.8	(49.8-228.1)	Female	9	10.3	87.6	(40.0-166.2)
Female	2	2.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	97	82.2	118.0	(95.7-144.0)
Male	5	2.3	220.8	(71.2-515.2)	<b><u>Stomach</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	11	6.4	172.2	(85.8-308.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	4.0	nc	(nc-nc)
Male	24	16.5	145.3	(93.1-216.2)	<b><u>Testis</u></b>				
Female	12	9.2	130.7	(67.5-228.3)	Male	2	4.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	4.0	nc	(nc-nc)	Male	6	8.0	75.0	(27.4-163.4)
Female	1	1.3	nc	(nc-nc)	Female	21	22.9	91.8	(56.8-140.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	11.2	98.1	(48.9-175.6)	Female	22	26.7	82.4	(51.6-124.7)
Female	9	8.3	108.5	(49.5-205.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	402	351.0	114.5	(103.6-126.3)
Male	9	9.8	91.8	(41.9-174.3)	Female	412	385.5	106.9	(96.8-117.7)
Female	4	3.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	50	46.4	107.8	(80.0-142.2)					
Female	71	51.7	137.4	(107.3-173.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millbury

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	16.2	135.9	(85.1-205.8)	Male	10	10.3	96.6	(46.3-177.7)
Female	2	5.1	nc	(nc-nc)	Female	8	7.3	109.8	(47.3-216.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	5	3.3	151.2	(48.7-352.9)
Female	2	2.4	nc	(nc-nc)	Female	6	2.4	249.4	(91.1-542.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	14	9.1	153.6	(83.9-257.7)
Female	64	59.6	107.4	(82.7-137.1)	Female	4	7.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.0	nc	(nc-nc)	Male	10	7.7	129.1	(61.8-237.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	16.8	71.4	(36.8-124.7)	Female	7	5.1	136.5	(54.7-281.2)
Female	12	14.6	82.2	(42.4-143.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	6.0	99.6	(36.4-216.8)
Male	7	4.1	170.3	(68.2-350.9)	Female	9	5.3	170.4	(77.7-323.4)
Female	3	1.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	54	50.8	106.2	(79.8-138.6)
Male	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.0	nc	(nc-nc)
Male	10	9.5	105.3	(50.4-193.6)	<b><u>Testis</u></b>				
Female	7	4.8	147.3	(59.0-303.6)	Male	1	1.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	2.4	250.7	(91.6-545.7)	Male	10	4.1	242.1	(115.9-445.2)
Female	1	0.7	nc	(nc-nc)	Female	13	11.1	117.0	(62.3-200.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	6.4	155.5	(74.4-286.0)	Female	12	13.7	87.6	(45.2-153.0)
Female	6	4.1	145.0	(52.9-315.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	253	207.7	121.8	(107.3-137.8)
Male	5	5.7	87.5	(28.2-204.2)	Female	210	196.8	106.7	(92.8-122.2)
Female	1	1.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	49	28.7	170.7	(126.3-225.7)					
Female	32	27.6	116.0	(79.3-163.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millis

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	6.1	130.3	(56.1-256.7)	Male	4	4.5	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	6	4.4	137.6	(50.2-299.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	39	36.2	107.7	(76.6-147.2)	Female	6	4.1	146.2	(53.4-318.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.2	nc	(nc-nc)	Male	6	3.8	156.4	(57.1-340.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	7.5	106.8	(46.0-210.4)	Female	1	3.1	nc	(nc-nc)
Female	8	8.3	96.0	(41.3-189.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	30	22.9	131.0	(88.4-187.0)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	4.5	131.9	(48.2-287.1)	Female	8	8.3	95.8	(41.3-188.9)
Female	4	2.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	9	11.4	78.7	(35.9-149.4)
Female	1	1.0	nc	(nc-nc)	Female	23	15.7	146.5	(92.8-219.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millville

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	15	14.6	103.0	(57.6-170.0)	Female	1	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.9	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	11	7.9	138.4	(69.0-247.7)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.0	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	40	32.1	124.8	(89.1-169.9)
Male	2	1.0	nc	(nc-nc)	Female	38	47.2	80.4	(56.9-110.4)
Female	1	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	7	3.9	180.3	(72.2-371.5)					
Female	9	6.4	140.6	(64.2-267.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	29.1	58.5	(34.0-93.6)	Male	35	18.3	191.7	(133.5-266.6)
Female	7	10.9	64.2	(25.7-132.3)	Female	24	15.0	160.4	(102.7-238.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	5.4	nc	(nc-nc)	Male	7	5.8	120.7	(48.4-248.7)
Female	6	4.9	121.4	(44.3-264.2)	Female	10	5.0	200.0	(95.7-367.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	21	16.1	130.1	(80.5-198.9)
Female	153	118.3	129.4	(109.7-151.6)	Female	10	14.8	67.6	(32.4-124.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.0	nc	(nc-nc)	Male	7	13.2	53.2	(21.3-109.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	25	30.1	83.2	(53.8-122.8)	Female	18	10.2	176.3	(104.4-278.7)
Female	29	31.3	92.5	(62.0-132.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	10.5	113.9	(58.8-198.9)
Male	8	7.1	113.0	(48.7-222.7)	Female	11	11.5	96.0	(47.8-171.7)
Female	4	2.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	93	82.0	113.5	(91.6-139.0)
Male	2	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	1.8	nc	(nc-nc)	Male	6	6.7	89.3	(32.6-194.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	4.4	nc	(nc-nc)
Male	16	16.1	99.2	(56.7-161.2)	<b><u>Testis</u></b>				
Female	11	9.5	115.8	(57.7-207.1)	Male	0	3.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	6	7.1	84.2	(30.8-183.4)
Female	0	1.3	nc	(nc-nc)	Female	34	21.9	155.0	(107.4-216.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	14	11.8	119.1	(65.1-199.9)	Female	27	26.2	103.0	(67.9-149.9)
Female	8	8.8	90.6	(39.0-178.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	351	359.0	97.8	(87.8-108.6)
Male	8	9.7	82.7	(35.6-162.9)	Female	451	401.1	112.5	(102.3-123.3)
Female	1	3.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	38	49.9	76.1	(53.9-104.5)					
Female	48	56.2	85.5	(63.0-113.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monroe

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monson

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	11.0	82.1	(37.5-155.9)	Male	4	7.1	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.2	80.2	(25.8-187.1)
Female	50	44.5	112.3	(83.3-148.0)	Female	7	4.9	142.0	(56.9-292.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	1	5.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	11	11.6	94.8	(47.2-169.6)	Female	0	3.7	nc	(nc-nc)
Female	5	9.7	51.8	(16.7-120.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	3	2.9	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	33	35.3	93.5	(64.3-131.3)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	5	6.6	75.8	(24.4-176.8)	Male	0	2.6	nc	(nc-nc)
Female	0	3.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	4	4.3	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	4	8.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	4.0	nc	(nc-nc)	Female	6	10.5	57.1	(20.8-124.3)
Female	1	1.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	16	19.7	81.2	(46.4-131.8)	Male	112	142.9	78.4	(64.5-94.3)
Female	14	18.6	75.3	(41.1-126.3)	Female	114	139.6	81.7	(67.4-98.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Montague

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	10.3	97.4	(46.6-179.1)	Male	8	6.4	125.0	(53.8-246.2)
Female	3	4.1	nc	(nc-nc)	Female	1	5.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	1.8	275.6	(88.8-643.2)	Male	4	2.1	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	5.7	106.1	(38.8-231.0)
Female	38	44.5	85.4	(60.4-117.3)	Female	3	5.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.4	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	10.4	67.2	(26.9-138.5)	Female	6	3.9	154.8	(56.5-337.0)
Female	12	11.8	101.6	(52.4-177.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	3.8	nc	(nc-nc)
Male	8	2.6	311.6	(134.2-614.0)	Female	2	4.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	17	31.1	54.7	(31.8-87.6)
Male	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.7	nc	(nc-nc)
Male	5	5.7	87.5	(28.2-204.2)	<b><u>Testis</u></b>				
Female	4	3.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	7.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	4.0	125.7	(40.5-293.3)	Female	9	10.4	86.4	(39.4-164.1)
Female	6	3.2	184.9	(67.5-402.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	121	128.5	94.2	(78.1-112.5)
Male	5	3.5	141.4	(45.6-330.0)	Female	124	150.8	82.2	(68.4-98.0)
Female	0	1.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	17.9	106.2	(63.9-165.9)					
Female	20	21.3	93.7	(57.2-144.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monterey

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	6	5.0	120.4	(44.0-262.1)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	3	5.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	13	21.3	61.0	(32.4-104.3)
Male	0	0.6	nc	(nc-nc)	Female	11	17.1	64.2	(32.0-114.9)
Female	1	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	3.0	nc	(nc-nc)					
Female	0	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	4.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	1.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	3.6	222.3	(95.7-438.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	2	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	0	2.0	nc	(nc-nc)	Male	16	14.4	110.8	(63.3-179.9)
Female	0	1.9	nc	(nc-nc)	Female	6	14.2	42.2	(15.4-91.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)					
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Stomach</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<b><u>Leukemia</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nahant

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.4	111.5	(40.7-242.6)	Male	6	3.2	189.4	(69.1-412.2)
Female	0	2.1	nc	(nc-nc)	Female	7	2.7	257.9	(103.3-531.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	19	21.5	88.4	(53.2-138.1)	Female	3	2.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.6	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	5.1	116.8	(42.7-254.3)	Female	0	1.9	nc	(nc-nc)
Female	7	6.1	114.7	(45.9-236.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	1.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	24	16.0	149.7	(95.9-222.8)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	2.8	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	3	2.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.8	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	13	9.3	140.0	(74.5-239.4)	Male	80	64.6	123.9	(98.3-154.2)
Female	7	10.5	66.8	(26.7-137.6)	Female	67	74.3	90.2	(69.9-114.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nantucket

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.5	69.4	(29.9-136.7)	Male	15	7.7	194.8	(109.0-321.4)
Female	4	3.4	nc	(nc-nc)	Female	16	5.1	314.3	(179.6-510.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	7	2.5	281.2	(112.6-579.3)
Female	2	1.7	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
Female	54	41.2	131.2	(98.5-171.1)	Female	5	4.8	103.8	(33.4-242.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	9	5.8	155.0	(70.7-294.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	10	12.3	81.3	(38.9-149.6)	Female	4	3.5	nc	(nc-nc)
Female	16	9.8	163.5	(93.4-265.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	31	36.5	85.0	(57.7-120.6)
Female	4	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	7.1	nc	(nc-nc)	Female	9	9.5	94.6	(43.2-179.6)
Female	0	3.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	7	4.8	147.2	(59.0-303.3)
Female	0	0.5	nc	(nc-nc)	Female	5	2.9	174.5	(56.2-407.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	2	4.2	nc	(nc-nc)	Male	16	20.8	76.8	(43.9-124.7)
Female	0	1.2	nc	(nc-nc)	Female	20	18.5	108.3	(66.1-167.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Natick

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	34.3	81.7	(54.3-118.1)	Male	21	22.4	93.6	(57.9-143.0)
Female	15	13.2	113.5	(63.5-187.2)	Female	19	19.5	97.7	(58.8-152.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.9	72.7	(23.4-169.7)	Male	5	7.1	70.1	(22.6-163.6)
Female	7	6.3	111.3	(44.6-229.4)	Female	5	6.2	80.3	(25.9-187.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	1.2	nc	(nc-nc)	Male	18	19.9	90.3	(53.5-142.7)
Female	127	160.0	79.4	(66.2-94.4)	Female	15	18.6	80.7	(45.2-133.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	5.4	nc	(nc-nc)	Male	19	16.7	113.6	(68.4-177.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	37	36.4	101.6	(71.5-140.1)	Female	19	13.5	140.9	(84.8-220.1)
Female	48	37.9	126.5	(93.3-167.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	14	12.8	109.4	(59.8-183.6)
Male	9	8.7	102.9	(47.0-195.4)	Female	12	13.6	88.3	(45.6-154.3)
Female	4	2.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	102	104.6	97.5	(79.5-118.3)
Male	2	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	2.4	nc	(nc-nc)	Male	9	8.1	110.7	(50.5-210.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	5.3	nc	(nc-nc)
Male	23	20.5	112.2	(71.1-168.3)	<b><u>Testis</u></b>				
Female	10	12.6	79.5	(38.1-146.2)	Male	8	5.4	147.7	(63.6-291.1)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	5.1	117.9	(43.1-256.6)	Male	12	9.5	125.7	(64.9-219.5)
Female	4	1.7	nc	(nc-nc)	Female	30	30.7	97.7	(65.9-139.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	14.3	105.1	(58.8-173.3)	Female	39	36.0	108.4	(77.0-148.1)
Female	5	10.9	45.9	(14.8-107.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	423	444.6	95.1	(86.3-104.6)
Male	9	12.2	73.8	(33.7-140.2)	Female	474	520.9	91.0	(83.0-99.6)
Female	3	4.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	47	60.4	77.8	(57.2-103.5)					
Female	62	72.0	86.1	(66.0-110.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Needham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	43	37.7	114.2	(82.6-153.8)	Male	36	23.2	155.4	(108.8-215.2)
Female	16	13.4	119.6	(68.3-194.3)	Female	22	17.9	123.1	(77.1-186.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.6	106.5	(42.6-219.4)	Male	10	7.4	134.5	(64.4-247.4)
Female	11	5.7	191.6	(95.5-342.8)	Female	6	6.1	97.7	(35.7-212.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	25	20.5	122.2	(79.1-180.4)
Female	177	143.5	123.4	(105.9-142.9)	Female	24	17.9	134.1	(85.9-199.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.6	nc	(nc-nc)	Male	7	16.5	42.4	(17.0-87.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	26	38.2	68.1	(44.5-99.8)	Female	11	12.4	88.9	(44.3-159.1)
Female	44	38.8	113.3	(82.3-152.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	13.6	51.6	(20.7-106.2)
Male	9	9.1	99.1	(45.2-188.2)	Female	16	14.2	112.3	(64.2-182.4)
Female	2	2.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	120	105.6	113.7	(94.2-135.9)
Male	2	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	3	8.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	5.5	nc	(nc-nc)
Male	20	20.3	98.6	(60.2-152.4)	<b><u>Testis</u></b>				
Female	14	11.5	121.7	(66.5-204.2)	Male	4	4.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	12	8.6	139.7	(72.1-244.0)
Female	0	1.6	nc	(nc-nc)	Female	32	25.3	126.5	(86.5-178.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	13	14.7	88.3	(47.0-151.1)	Female	33	31.9	103.4	(71.1-145.2)
Female	15	10.8	139.5	(78.0-230.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	426	457.2	93.2	(84.5-102.5)
Male	7	12.4	56.5	(22.6-116.3)	Female	513	486.4	105.5	(96.5-115.0)
Female	4	4.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	40	64.1	62.4	(44.6-84.9)					
Female	38	67.9	56.0	(39.6-76.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
					Male 4 5.9 nc (nc-nc)				
					Female 5 5.1 97.6 (31.4-227.7)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	96	97.6	98.3	(79.6-120.1)	Male	25	62.2	40.2	(26.0-59.3)
Female	25	39.4	63.5	(41.1-93.8)	Female	17	52.6	32.3	(18.8-51.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	18.6	53.7	(25.7-98.8)	Male	20	19.8	101.0	(61.6-155.9)
Female	11	17.3	63.5	(31.7-113.7)	Female	15	18.0	83.5	(46.7-137.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	46	55.3	83.2	(60.9-110.9)
Female	340	406.9	83.6	(74.9-92.9)	Female	48	52.6	91.3	(67.3-121.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	17	13.2	128.9	(75.0-206.3)	Male	46	45.0	102.1	(74.8-136.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	120	101.4	118.3	(98.1-141.5)	Female	30	36.0	83.4	(56.3-119.1)
Female	104	113.1	92.0	(75.1-111.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	37	35.8	103.4	(72.8-142.6)
Male	24	24.1	99.5	(63.7-148.1)	Female	50	41.7	119.9	(89.0-158.1)
Female	9	7.6	118.9	(54.3-225.8)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	315	281.4	111.9	(99.9-125.0)
Male	8	7.6	105.4	(45.4-207.8)	<b><u>Stomach</u></b>				
Female	5	6.9	72.2	(23.3-168.5)	Male	38	22.7	167.4	(118.5-229.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	19	15.9	119.2	(71.7-186.1)
Male	57	54.9	103.8	(78.6-134.5)	<b><u>Testis</u></b>				
Female	40	33.3	120.1	(85.8-163.6)	Male	9	14.6	61.6	(28.1-116.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	32	13.9	229.5	(157.0-324.0)	Male	20	25.0	79.9	(48.8-123.4)
Female	6	4.6	130.3	(47.6-283.7)	Female	84	74.8	112.3	(89.5-139.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	35	39.6	88.4	(61.6-123.0)	Female	73	91.2	80.1	(62.8-100.7)
Female	21	32.2	65.2	(40.3-99.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	1349	1224.5	110.2	(104.4-116.2)
Male	59	33.5	176.3	(134.2-227.5)	Female	1274	1410.9	90.3	(85.4-95.4)
Female	15	12.8	117.2	(65.5-193.3)					
<b><u>Lung and Bronchus</u></b>									
Male	257	168.1	152.9	(134.8-172.8)					
Female	204	198.5	102.8	(89.2-117.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	6	4.2	143.1	(52.3-311.5)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.5	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	20	16.0	124.7	(76.1-192.5)
Male	0	0.5	nc	(nc-nc)	Female	14	16.1	87.0	(47.5-145.9)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	2.0	nc	(nc-nc)					
Female	2	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	9	9.0	99.5	(45.4-188.9)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	2	8.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
					Male	18	34.2	52.6	(31.2-83.2)
					Female	22	29.3	75.0	(47.0-113.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Salem

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.9	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Male</u></b>				
Male	0	0.2	nc	(nc-nc)	14	19.0	73.6	(40.2-123.5)	
Female	0	0.1	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Leukemia</u></b>					<b><u>15</u></b>				
Male	0	0.6	nc	(nc-nc)	17.8	84.1	(47.0-138.8)		
Female	1	0.4	nc	(nc-nc)					
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	2.5	nc	(nc-nc)					
Female	1	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;